Personalised health care : fostering precision medicine advancements for gaining population health impact
著者
書誌事項
Personalised health care : fostering precision medicine advancements for gaining population health impact
（SpringerBriefs in public health）
Springer, c2021
大学図書館所蔵 件 / 全2件
-
該当する所蔵館はありません
- すべての絞り込み条件を解除する
注記
Includes bibliographical references and index
内容説明・目次
内容説明
Practitioners are increasingly adopting a personalised medicine approach to individually tailored patient care, especially disease diagnosis and treatment with the use of biomarkers. However, development and implementation of such approaches to chronic disease prevention need further investigation and concerted efforts for proper use in healthcare systems. This book provides high-quality, multidisciplinary knowledge from research in personalised medicine, specifically personalised prevention of chronic disease. It addresses different perspectives of prevention in the field, and is the outcome of a four-year work of the Personalized prevention of Chronic Disease (PRECeDI) Consortium, a multi-disciplinary and multi-professional team of experts.
The Consortium jointly agreed to document and address the five aspects or domains of personalised medicine and prevention as individual chapters:
Identification of biomarkers for the prevention of chronic disease
Evaluation of predictive genomic applications
Ethico-legal and policy issues surrounding personalised medicine
Roles and responsibilities of stakeholders in informing healthy individuals on their genome: a sociotechnical analysis
Identification of organisational models for the provision of predictive genomic applications
The book focuses on the Consortium's recommendations that are derived from each of these domains based on up-to-date evidence and research that the authors write, follow, and systematically organise and report.
Personalisation of health care is, eventually, a driver of innovation in research and healthcare systems. With this SpringerBrief on Personalised Health Care: Fostering Precision Medicine Advancements for Gaining Population Health Impact, the Consortium provides further evidence of the clinical validity and utility of personalised medicine with special emphasis on the prevention of chronic diseases. The book is a useful resource for policy makers, industry and healthcare professionals, scientists, technology-sector professionals, investors, citizens, and private companies that need proper advice to realise the potential of personalised medicine.
目次
Introduction (Boccia)
1. Chapter 1: Identification of biomarkers for the prevention of chronic disease (Editors: Adany, Boccia).
1.1 Van Duijn (Identification of biomarkers for primary and secondary prevention - Liu)1.2 Boccia (Identification of biomarkers for tertiary prevention - Mariani, Giraldi, Pastorino)1.3 Adany (Application of Single-Nucleotide Polymorphism-Related Risk Estimates in Identification of Increased Genetic Susceptibility to Specific Diseases)1.4 Giordano Botta - Allelica (Non Academic Vision) Recommendation 1
Personalised interventions for the prevention of chronic diseases require robust evidence of efficacy and/or effectiveness of the new technology when implemented in health care.
2. Chapter 2: Evaluation of predictive genomic applications (Editor: Villari)
2.1 The economic evaluation of genetic/genomic applications (D'Andrea)2.2 The HTA approach for the evaluation of genetic/genomic applications (Pitini)2.3 Training needs in genomics of Public Health Professionals (Rosso)
Recommendation 2A comprehensive evaluation of the value (outcomes/cost) of the new technology should also include evidence on the social aspects, and context-related dimensions to better support the clinical decision-making process. Genetic or genomic applications with evidence of efficacy, effectiveness, and cost-effectiveness should be implemented in clinical and public health practice.
3. Chapter 3: Ethico-legal and policy issues surrounding personalised medicine (Editor: Sandor)
3.1 Zawati (Ethical issue) 3.2 Calabro, Hoxaij, Boccia (Policy issue, with a focus on training in genomics for healthcare professionals)3.3 Calabro, Sassano, Boccia (Policy issue, with a focus on citizens and DTC)3.4 Sandor (Legal issue)
Recommendation 3The era of genomics requires that we clarify and validate the obligations and responsibilities of the research community, research participants, and the general public including patients through collaboration and dissemination of high-quality ethical, policy, and legal analysis.
4. Chapter 4: Roles and responsibilities of stakeholders in informing healthy individuals on their genome: a sociotechnical analysis (Editor: Cornel)
(Martina Cornel, Tessel Rigter, and Carla van El)4.1 Responsible translation of new genomic technologies in the context of screening of healthy adults4.2 Examples from hereditary cardiovascular diseases and hereditary cancers
Recommendation 4 A dedicated effort is necessary to stimulate further implementation of evidence-based interventions in health care, such as testing of family members in cases of hereditary cancers or cardiovascular diseases.
5. Chapter 5: Identification of organizational models for the provision of predictive genomic applications (Editor: De Vito)
5.1 De Vito/Unim (Delivery models for genetic/genomic applications)5.2 Cornel (Barriers and Facilitating Factors for Implementation of Genetic Services)5.3 Gray/Jani (Design systems that integrate genomic information to deliver personalised care)5.4 Roldan (Clinical decision support tool to assist physicians in the screening of genetic diseases)
Recommendation 5 The integration of genomic sciences in other medical specialties should be promoted through new delivery models involving different healthcare professionals and new professional roles, in order to guarantee the use and sustainability of existing and new genomic applications in practice.
Each Chapter is approximately 25 pages
「Nielsen BookData」 より
